

9/23 (Sat.) 13:50-14:20

Gene Assay Tools to Inform Chemotherapy Benefit in HR+ HER2- Anatomically High Risk Early Breast Cancer

Kevin Kalinsky, M.D., M.S.

Data from the large, randomized, phase III trials with genomic assays will be reviewed, including TailorX, RxPONDER, and MINDACT. There will be a focus on premenopausal women. Limitations of these trials will be reviewed, including the relatively small number of premenopausal women who underwent ovarian function suppression. Whether the chemotherapy benefit in the premenopausal population is due to tumor biology differences in young vs. older women or solely due to the amenorrhea effect from chemotherapy will also be discussed. Updates from recent congresses will be reviewed, as well as future directions.